TY - JOUR
T1 - Outcome of intestinal transplants for patients with Crohn's disease
AU - Desai, C. S.
AU - Khan, K.
AU - Gruessner, A.
AU - Gruessner, R.
PY - 2013/11
Y1 - 2013/11
N2 - Background: The pathophysiology of Crohn's disease (CD) is related to immune dysregulation making it unique among indications for intestinal transplants (ITx). We examined whether outcomes of ITx for CD are any worse than the overall ITx population. Methods: United Network for Organ Sharing Standard Transplant Analysis and Research files were analyzed. Adult ITx recipients from 1987 to 2009 were included. Results: Of 86 primary ITx for CD, 61 (70%) had isolated ITx and 25 (30%) had liver-ITx (L-ITx). The 1-, 3-, and 5-year patient survival for isolated ITx was 85%, 67%, and 54%; for L-ITx, 63%, 47%, and 41% (P =.04). The graft survival at 1, 3, and 5 years was 85%, 55%, and 45% for isolated ITx recipients and 63%, 47%, and 41% for L-ITx recipients (Wilcoxon's test, P =.04). Patient and graft survival was better in era 2 (January 2001 through August 2009) than in era 1 (October 1987 through December 2000). In the regression analysis of long-term outcome of adults undergoing ITx, recipient age > 40 years and hospitalization prior to transplantation were negative predictors of outcome. Conclusion: Patient and graft survival for CD patients is not inferior to other indications for ITx.
AB - Background: The pathophysiology of Crohn's disease (CD) is related to immune dysregulation making it unique among indications for intestinal transplants (ITx). We examined whether outcomes of ITx for CD are any worse than the overall ITx population. Methods: United Network for Organ Sharing Standard Transplant Analysis and Research files were analyzed. Adult ITx recipients from 1987 to 2009 were included. Results: Of 86 primary ITx for CD, 61 (70%) had isolated ITx and 25 (30%) had liver-ITx (L-ITx). The 1-, 3-, and 5-year patient survival for isolated ITx was 85%, 67%, and 54%; for L-ITx, 63%, 47%, and 41% (P =.04). The graft survival at 1, 3, and 5 years was 85%, 55%, and 45% for isolated ITx recipients and 63%, 47%, and 41% for L-ITx recipients (Wilcoxon's test, P =.04). Patient and graft survival was better in era 2 (January 2001 through August 2009) than in era 1 (October 1987 through December 2000). In the regression analysis of long-term outcome of adults undergoing ITx, recipient age > 40 years and hospitalization prior to transplantation were negative predictors of outcome. Conclusion: Patient and graft survival for CD patients is not inferior to other indications for ITx.
UR - http://www.scopus.com/inward/record.url?scp=84887091278&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887091278&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2012.04.030
DO - 10.1016/j.transproceed.2012.04.030
M3 - Article
C2 - 23267810
AN - SCOPUS:84887091278
SN - 0041-1345
VL - 45
SP - 3356
EP - 3360
JO - Transplantation Proceedings
JF - Transplantation Proceedings
IS - 9
ER -